Hyperlipidemia and atherosclerosis in experimental insulinopenic diabetic monkeys. 1992

Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
Third Department of Medicine, Shiga University of Medical Science, Japan.

Chronic insulinopenic diabetes was induced by i.v. streptozotocin in the non-human primate Macaca fuscata. Five diabetic monkeys were kept for 8-19 months and nine for 24-48 months without any insulin treatment. Hyperglycemia (241 +/- 22 mg/dl, M +/- SE less than or equal to 1 year) progressed to 376 +/- 34 mg/dl (greater than 2 years) and ketosis to 3.5 mM (greater than 2 years) during the course of diabetes; this was roughly inversely proportional to hypoinsulinemia (3.4 microU/ml, 2 years). Serum cholesterol increased from 184 +/- 11 (less than or equal to 1 year) to 328 +/- 66 mg/dl (greater than 2 years) with the major increase in LDL-cholesterol (2.7-fold over control, greater than 2 years). HDL-cholesterol did not change at all throughout the experimental period. TG increased from 144 +/- 25 (less than or equal to 1 year) to 676 +/- 116 (greater than 2 years) with a major increase in the VLDL fraction (15-fold over control, greater than 2 years). Serum levels of apo B increased to 141 +/- 16 (less than or equal to 2 years) and 223 +/- 8 mg/dl (greater than 2 years) in contrast to control, 73 +/- 2. Morphologically, lipid deposition in the intima and fatty streaks have been observed in the abdominal aorta of all the diabetic monkeys with duration of more than 2 years. In six of the diabetic monkeys atheromatous changes such as intimal and medial thickening with smooth muscle cell proliferation were observed with foam cell formation. Similar atherosclerotic lesions were observed in renal and coronary arteries in at least six of these monkeys. In diabetic monkeys with duration of less than 2 years, mild atherosclerotic lesions were observed in two out of five. The results indicate that long standing insulinopenia leads to metabolic derangements characterized by hyperglycemia, ketonemia and hyperlipidemia. Elevation of LDL-cholesterol and VLDL TG with an increase of apo B is a characteristic of lipoprotein disorder. Morphologically, early to moderately advanced lesions of atherosclerosis were observed in aorta, renal and coronary arteries as a result of metabolic derangement due to insulin deficiency.

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007657 Ketone Bodies The metabolic substances ACETONE; 3-HYDROXYBUTYRIC ACID; and acetoacetic acid (ACETOACETATES). They are produced in the liver and kidney during FATTY ACIDS oxidation and used as a source of energy by the heart, muscle and brain. Acetone Bodies,Bodies, Acetone,Bodies, Ketone
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008251 Macaca A genus of the subfamily CERCOPITHECINAE, family CERCOPITHECIDAE, consisting of 16 species inhabiting forests of Africa, Asia, and the islands of Borneo, Philippines, and Celebes. Ape, Barbary,Ape, Black,Ape, Celebes,Barbary Ape,Black Ape,Celebes Ape,Macaque,Apes, Barbary,Apes, Black,Apes, Celebes,Barbary Apes,Black Apes,Celebes Apes,Macacas,Macaques
D008297 Male Males
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart

Related Publications

Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
November 1980, Therapeutische Umschau. Revue therapeutique,
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
September 1953, The Journal of experimental medicine,
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
February 1984, Diabetes,
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
January 2005, Pharmacological reports : PR,
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
February 1988, Experimental and molecular pathology,
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
October 1966, The Journal of pathology and bacteriology,
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
July 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
May 2002, Nihon rinsho. Japanese journal of clinical medicine,
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
January 1980, Indian heart journal: teaching series,
Y Harano, and H Kojima, and K Kosugi, and M Suzuki, and M Harada, and T Nakano, and H Hidaka, and A Kashiwagi, and R Torii, and Y Taniguchi
September 1976, Science (New York, N.Y.),
Copied contents to your clipboard!